Epigenetic mechanisms driving tumor supportive microenvironment differentiation and function: a role in cancer therapy?

Epigenomics. 2020 Jan;12(2):157-169. doi: 10.2217/epi-2019-0165. Epub 2019 Dec 18.

Abstract

The tumor microenvironment (TME) plays a central role in tumor development and drug resistance. Within TME, the stromal cell subset, called cancer-associated fibroblasts, is a heterogeneous population originating from poorly characterized precursors. Since cancer-associated fibroblasts do not acquire somatic mutations, other mechanisms like epigenetic regulation, could be involved in the development of these cells and in the acquisition of tumor supportive phenotypes. Moreover, such epigenetic modulations have been correlated to the emergence of an immunosuppressive microenvironment facilitating tumor evasion. These findings underline the need to deepen our knowledge on epigenetic mechanisms driving TME development and function, and to understand the impact of epigenetic drugs that could be used in future to target both tumor cells and their TME.

Keywords: cancer; cancer-associated fibroblasts; epigenetic; microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cancer-Associated Fibroblasts / metabolism
  • Epigenesis, Genetic* / drug effects
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Immune Tolerance
  • Neoplasms / drug therapy
  • Neoplasms / genetics*
  • Neoplasms / immunology
  • Neoplasms / metabolism
  • Tumor Microenvironment* / drug effects

Substances

  • Antineoplastic Agents